Michael Rusnak

  • Sam Patrick posted an article
    MUSC, Cumberland Emerging Technologies collaborate to develop biomedical products see more

    The technology transfer organization for the Medical University of South Carolina, the MUSC Foundation for Research Development, and Cumberland Emerging Technologies Inc. have entered into a collaboration agreement to develop new biomedical products.

    Consistent with their longstanding commitment to biomedical innovation and translational research, CET and the MUSC Foundation for Research Development have agreed to collaborate on future co-development programs that combine the strengths of each institution with the goal of advancing new technology to clinical practice.  Under the agreement, CET will evaluate MUSC discoveries, license intellectual property rights to promising technologies, and partner with MUSC research scientists to advance product development toward commercialization.  CET will pursue new sources of funding for these projects through the Small Business Technology Transfer and Small Business Innovation Research and other grant programs. New development programs are expected to span a variety of therapeutic areas including oncology, inflammatory diseases, and cardiovascular disease. 

    "Our office receives over 100 product ideas a year, most of which require an industry partner to be further developed," said Michael Rusnak, the executive director of the MUSC Foundation for Research Development. "We are very enthusiastic about having Cumberland as a collaborator to aid in getting technologies to market and ultimately to the patient."

    "We are very pleased to have the opportunity to partner with the MUSC Foundation for Research Development to develop technologies invented at MUSC, a nationally-recognized biomedical research institution," said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals and CET. "We are excited to facilitate the introduction of promising new products by combining our expertise in drug development and commercialization with the MUSC's research initiatives."

  • Sam Patrick posted an article
    Top life sciences leaders from across the state have been named to the SCBIO Executive Committee see more

    Leadership team provides strategic blend of economic development, industry, higher education expertise

     

    GREENVILLE, SC – January 17, 2019 – SCBIO has announced its 2019 Executive Committee following formal confirmation at the life science organization’s December 2018 meeting in Columbia.  Nephron Pharmaceuticals Corporation CEO Lou Kennedy will serve a second term as SCBIO’s 2019 Board Chair.

    Ms. Kennedy joined Nephron Pharmaceuticals in 2001, and assumed the position of President and CEO in 2007. She has held a variety of marketing and operational roles during her career and has helped Nephron Pharmaceuticals grow by more than 300% and increased shipped product to one billion doses each of the last seven years.  Nephron constructed a state of the art manufacturing facility in West Columbia, South Carolina and, with her husband Bill, helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy.  The organization was honored as an inaugural winner of the South Carolina Life Sciences Pinnacle Award for Organizational Contribution to the industry in October, 2018.

    Joining Ms. Kennedy on the SCBIO Executive Committee will be Stephanie Yarbrough, Partner with Womble Bond Dickinson, LLP as Vice Chair; Michael Rusnak, Executive Director of the MUSC Foundation for Research Development as Treasurer; and Josh Ridley, Global Business Development Director of ZEUS as Secretary.  

    Additional members of the Executive Committee are Jeff Stover, Special Counsel with Haynsworth Sinkler Boyd, PA as Legal Officer; Heather Simmons Jones, CEO of the Greenwood Partnership Alliance as Annual Conference Officer; Bryan Davis, Operations Manager with Greenville Health System’s Office of Innovations as Healthcare/Innovation Officer; Adam Hoots, Life Sciences Market Leader for DPR Construction as Talent/Workforce Officer; and Sam Konduros, President and CEO of SCBIO. 

    Recognized for completing their terms as contributing members of the SCBIO Executive Committee were former Vice Chair Craig Walker, executive with Hitachi Healthcare Americas, and former Secretary Kathryn Becker, Principal with Translational Science Solutions LLC.

    SCBIO President and CEO Konduros praised the Executive Committee noting, “With the critically important efforts we are undertaking to advance pharmaceuticals, life sciences R&D, biotech, med-tech, and the health IT industries in South Carolina, we require strong, expert leadership from across the state, fully integrating our business, education and economic development sectors. These diverse leaders who represent the width and breadth of our state and industry will effectively champion our vision of building the business of life sciences in South Carolina for years to come.”

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry already has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.

    The Executive Committee and Board of Directors is the policy- and strategy-making body of the organization, and meets regularly to receive updates on SCBIO business and objectives, as well as domestic and global initiatives. The Executive Committee serves roles specific to SCBIO operations, focus areas and strategies.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.

    For additional information on SCBIO, visit www.SCBIO.org

  • Sam Patrick posted an article
    SCBIO has named its 2018 Board of Directors and Board Chair see more

    SCBIO has announced its 2018 Board of Directors and Executive Committee following formal confirmation at the life science organization’s December 2017 meeting in Columbia.  Nephron Pharmaceuticals Corporation CEO Lou Kennedy will serve as SCBIO’s 2018 Board Chair.

    Ms. Kennedy joined Nephron Pharmaceuticals in 2001, and assumed the position of President and CEO in 2007. She has held a variety of marketing and operational roles during her career and has helped Nephron Pharmaceuticals grow by 300% and increased shipped product to one billion doses each of the last seven years.  Nephron recently built a state of the art manufacturing facility in West Columbia, South Carolina and, with her husband Bill, helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy.

    Joining Ms. Kennedy as officers on the SCBIO Executive Committee will be Craig Walker, CEO of VidiStar LLC as Vice Chair; Michael Rusnak, Executive Director of the Medical University of South Carolina Research Foundation as Treasurer; and Kathryn Cole Becker, Principal of Translational Science Solutions as Secretary.  Additional members of the Executive Committee are Jeff Stover, Special Counsel with Haynsworth Sinkler Boyd, PA as Legal Officer; Stephanie Yarbrough, Partner with Womble Bond Dickinson, LLP as Annual Conference Officer; Bryan Davis, Operations Manager with Greenville Health System’s Office of Innovations as Healthcare/Innovation Officer; and Sam Konduros, President and CEO of SCBIO.  Immediate Past Chair, Erin Ford, who now serves as the organization’s inaugural Vice President, was honored for her extraordinary board service during the December Board meeting.

    Also elected to the 22-member Board of Directors for SCBIO are Darralyn Alexander, President of Reimbursement Strategies LLC; Mandy Brawley, Deputy Director of the South Carolina Department of Commerce; Jerry Chang, Vice President of Business Development for BioD; Matthew Couvillion, Attorney with the Wyche Law Form; J.J. Darby, State Government Affairs Leader for Johnson & Johnson Services; Tressa Gardner, Associate Vice president of the Southeastern Institute of Manufacturing and Technology at Florence-Darlington Technical College; and Mike Graney, Vice President  for Global Business Development of the Charleston Regional Development Alliance.

    Completing the 2018 Board of Directors for SCBIO are Chad Hardaway, Associate Director of the Office of Economic Engagement at the University of South Carolina; Willard Harms, VP of Medical Affairs for Blue Cross Blue Shield of South Carolina; Dr. Martine LaBerge, Chair of Clemson University’s Department of Bioengineering; Marc Metcalf, Business Recruitment Officer of the Upstate SC Alliance; Kathy Phlegar, President of Phlegar & Associates; Christine Dixon Thiesing, Director of Academic Programs for the South Carolina Research Authority; and Courtney Warren, Life Sciences Practice Chair for Marsh & McLennan Agency.

    SCBIO President and CEO Konduros praised the Board and Executive Committee noting, “With the important work we are undertaking to actively advance life sciences R&D, biotech, med-tech, and digital health industries in South Carolina, we require strong, expert leadership from all across the state, fully integrating the business, education and economic development sectors. I am confident that these diverse leaders who reside in communities ranging from Murrells Inlet to Florence in addition to Greenville, Columbia, and Charleston, will effectively champion our vision of building the business of life sciences in South Carolina in 2018 and for years to come.”

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry already has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.

    The Board of Directors is the policy- and strategy-making body of the organization, and meets regularly to receive updates on SCBIO business and objectives, as well as domestic and global initiatives. The Executive Committee serves roles specific to SCBIO operations, focus areas and strategies.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.